SG Americas Securities LLC lessened its holdings in Bausch Health Companies Inc. (NYSE:BHC - Free Report) by 13.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,870,302 shares of the company's stock after selling 431,679 shares during the quarter. SG Americas Securities LLC owned approximately 0.78% of Bausch Health Companies worth $18,571,000 at the end of the most recent reporting period.
A number of other large investors have also added to or reduced their stakes in BHC. Maple Rock Capital Partners Inc. raised its holdings in Bausch Health Companies by 156.7% in the 4th quarter. Maple Rock Capital Partners Inc. now owns 5,300,000 shares of the company's stock valued at $42,718,000 after buying an additional 3,235,100 shares during the last quarter. Compass Rose Asset Management LP increased its position in Bausch Health Companies by 366.7% during the 4th quarter. Compass Rose Asset Management LP now owns 2,100,000 shares of the company's stock valued at $16,926,000 after purchasing an additional 1,650,000 shares during the period. Arrowstreet Capital Limited Partnership increased its position in Bausch Health Companies by 46.3% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 4,770,793 shares of the company's stock valued at $38,501,000 after purchasing an additional 1,510,445 shares during the period. O Shaughnessy Asset Management LLC increased its position in Bausch Health Companies by 989.1% during the 4th quarter. O Shaughnessy Asset Management LLC now owns 611,890 shares of the company's stock valued at $4,940,000 after purchasing an additional 555,709 shares during the period. Finally, Renaissance Technologies LLC increased its position in Bausch Health Companies by 1,761.5% during the 4th quarter. Renaissance Technologies LLC now owns 495,172 shares of the company's stock valued at $3,991,000 after purchasing an additional 468,572 shares during the period. Institutional investors own 78.65% of the company's stock.
Bausch Health Companies Price Performance
NYSE:BHC traded up $0.51 during trading hours on Friday, hitting $6.02. The company had a trading volume of 11,490,808 shares, compared to its average volume of 2,611,854. The company has a market capitalization of $2.23 billion, a PE ratio of -50.12, a price-to-earnings-growth ratio of 0.37 and a beta of 0.28. The stock has a 50-day moving average price of $4.85 and a 200 day moving average price of $6.42. Bausch Health Companies Inc. has a 52 week low of $3.96 and a 52 week high of $9.85.
Wall Street Analyst Weigh In
Several analysts have recently commented on the stock. Royal Bank of Canada raised their price objective on shares of Bausch Health Companies from $8.50 to $10.00 and gave the stock a "sector perform" rating in a research report on Friday, May 2nd. Wall Street Zen downgraded shares of Bausch Health Companies from a "buy" rating to a "hold" rating in a research report on Saturday, May 10th. One analyst has rated the stock with a sell rating and seven have given a hold rating to the stock. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $7.42.
Read Our Latest Analysis on Bausch Health Companies
Insider Transactions at Bausch Health Companies
In related news, Director John Paulson acquired 1,005,376 shares of the firm's stock in a transaction that occurred on Thursday, June 12th. The stock was purchased at an average cost of $5.47 per share, for a total transaction of $5,499,406.72. Following the purchase, the director now directly owns 29,227,643 shares of the company's stock, valued at $159,875,207.21. This trade represents a 3.56% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. In the last 90 days, insiders have bought 2,788,608 shares of company stock valued at $14,700,257. 8.05% of the stock is currently owned by corporate insiders.
Bausch Health Companies Profile
(
Free Report)
Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
See Also

Before you consider Bausch Health Cos, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch Health Cos wasn't on the list.
While Bausch Health Cos currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.